申请人:Wannamaker Marion W.
公开号:US20090048226A1
公开(公告)日:2009-02-19
The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1β converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-γ inducing factor-(IGIF), or interferon-γ-(“IFN-γ”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-γ production and methods for treating interleukin-1, apoptosis-, and interferon-γ-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.
本发明涉及一类新型化合物,它们是caspase抑制剂,特别是白细胞介素-1β转化酶(“ICE”)抑制剂。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制caspase活性,并因此可以作为对白细胞介素-1(“IL-1”)、凋亡、干扰素-γ诱导因子(IGIF)或干扰素-γ(“IFN-γ”)介导的疾病,包括炎症性疾病、自身免疫性疾病、破坏性骨疾病、增生性疾病、传染性疾病和退行性疾病的药剂。本发明还涉及抑制caspase活性、减少IGIF生成和IFN-γ生成的方法以及使用本发明的化合物和组合物治疗白细胞介素-1、凋亡和干扰素-γ介导的疾病的方法。本发明还涉及制备本发明化合物的方法。